FDA OK's GSK's Arnuity Ellipta in asthma
This article was originally published in Scrip
Executive Summary
The FDA on 20 August OK'd GlaxoSmithKline’s Arnuity Ellipta (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid maintenance treatment of asthma, as prophylactic therapy in patients 12 years or older.